EGFR and non-small cell lung carcinoma: We showed that both vorinostat and VPA were able to downregulate EGFR and ErbB2 expression in all our primary NSCLC cultures, as previously reported by us and others in different tumor cell models, including NSCLC cell lines [16, 20, 26–29].